BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270115
DTSTAMP:20261007T105217Z
CREATED:20261007T105217Z
LAST-MODIFIED:20261007T105217Z
UID:44495-1799712000-1799971199@www.pharmajournalist.com
SUMMARY:PFS & Injectable Drug Devices Europe
DESCRIPTION:PFS & Injectable Drug Devices Europe 2027 will bring together pharmaceutical\, biotechnology\, medical device and drug delivery professionals in London from 12–14 January 2027 to explore the latest innovations in pre-filled syringes\, injectable drug delivery devices\, combination products and primary packaging. \nNow in its 19th year\, the conference will provide a focused platform for industry leaders to discuss the technologies\, regulatory developments and market trends shaping the future of injectable drug delivery. The event is designed for professionals working across pharmaceutical development\, drug-device combination products\, medical devices\, pre-filled syringes\, primary packaging\, human factors\, regulatory affairs and manufacturing. \nThe three-day programme will feature presentations and discussions from experts across the pharmaceutical and biotechnology sectors. Key topics will include next-generation pre-filled syringe technologies\, large-volume drug delivery\, novel injectable delivery systems\, device development\, quality by design\, design controls\, human factors and patient-centric drug delivery. \nRegulatory and compliance considerations will also be a major focus\, with sessions exploring combination product regulations\, Article 117\, notified body requirements and evolving European regulatory expectations. These discussions will help companies understand the changing requirements for developing and commercialising injectable drug-device products in Europe. \nThe conference will also examine the growing importance of sustainability in pharmaceutical packaging and drug delivery devices\, including circular economy approaches\, lifecycle carbon assessment and sustainable packaging strategies. \nWith 250+ attendees\, 50+ expert speakers\, interactive roundtables and dedicated networking opportunities\, PFS & Injectable Drug Devices Europe 2027 offers pharmaceutical and biotech professionals an opportunity to share knowledge\, discover new technologies and connect with senior industry decision-makers. \nThe event is particularly relevant for professionals involved in pre-filled syringes\, injectable drug delivery\, combination products\, medical device development\, primary packaging\, pharmaceutical manufacturing\, regulatory affairs and human factors engineering. \nFor more information about the event\, Click Here.
URL:https://www.pharmajournalist.com/event/pfs-injectable-drug-devices-europe/
LOCATION:Marriott Hotel Grosvenor Square\, 10-13 Grosvenor Sq\, London\, W1K 6JP\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:Alessandra.DeMaria@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270115
DTSTAMP:20261110T124032Z
CREATED:20261110T124010Z
LAST-MODIFIED:20261110T124032Z
UID:44736-1799798400-1799971199@www.pharmajournalist.com
SUMMARY:Rational Based Drug Design Summit Europe
DESCRIPTION:The Rational Based Drug Design Summit Europe is the dedicated meeting for structural biologists\, biophysicists\, medicinal chemists\, computational chemists\, AI drug discovery experts and pharma leaders advancing next-generation therapeutics. Join Europe’s leading biopharma organisations to explore how structural biology\, biophysics\, medicinal chemistry and AI are accelerating target identification\, molecular design and candidate selection through case studies\, expert insights and networking opportunities. \nFind out more:  https://ter.li/10npaq8i
URL:https://www.pharmajournalist.com/event/rational-based-drug-design-summit-europe/
LOCATION:Park Plaza Victoria Amsterdam\, Damrak 1-5\, Amsterdam\, 1012 LG\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270122
DTSTAMP:20261002T122815Z
CREATED:20261002T122815Z
LAST-MODIFIED:20261002T122815Z
UID:44487-1800316800-1800575999@www.pharmajournalist.com
SUMMARY:5th Ophthalmic Drug Delivery Summit
DESCRIPTION:The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye. \nHear directly from leaders at Kodiak Sciences\, Re-Vana Therapeutics\, Ripple Therapeutics\, Eli Lilly\, Genentech\, Sanofi\, Astellas\, Apellis\, Beacon Therapeutics\, Kriya Therapeutics and more as they share the latest thinking on long-acting therapies\, novel delivery routes\, gene and cell therapy\, translational science and drug-device integration. \nWith clinical validation and investment accelerating across the field\, this industry-focused\, modality and indication-agnostic meeting offers a timely opportunity to benchmark emerging technologies\, learn from development successes and setbacks\, and connect with the experts tackling the biggest barriers to effective ocular delivery. \nExpect candid lessons\, emerging strategies and cross-functional perspectives spanning delivery\, formulation\, devices\, CMC\, clinical development\, regulatory strategy and commercialization. \nDon’t miss the only industry-focused\, modality\, and indication-agnostic forum dedicated to ophthalmic drug delivery. \nTo know more visit: https://ter.li/4m4gw2gg
URL:https://www.pharmajournalist.com/event/5th-ophthalmic-drug-delivery-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf San Francisco\, 555 North Point St\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20260925T061157Z
CREATED:20260925T060703Z
LAST-MODIFIED:20260925T061157Z
UID:44399-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:Muscular Disorders Drug Development Summit
DESCRIPTION:Muscular Disorders Drug Development Summit | January 26-28\, 2027 | Boston\, MA \nThe muscular disease field is entering a pivotal new chapter. Following a year of significant debate around Sarepta’s Elevidys\, the industry is rapidly evolving as a new wave of gene therapies\, RNA medicines\, stem cell therapies\, and small molecules advance through development. With anticipated regulatory milestones from companies including Regenxbio\, Capricor\, and Avidity Biosciences\, alongside growing investment and renewed pharmaceutical interest\, momentum has never been stronger across muscular dystrophies\, Pompe disease\, and related myopathies. \nThe inaugural Muscular Disorders Drug Development Summit is the only industry-focused forum dedicated to helping biopharma leaders accelerate the translation\, clinical development\, and delivery of next-generation therapies for muscle disorders. \nBe the first to access the newly launched event program. \nAcross three days of expert-led presentations\, interactive discussion\, and dedicated networking\, attendees will: \n\nDiscover lessons learned from approved and late-stage muscular disease therapies\nExplore emerging modalities beyond traditional gene therapy\nAdvance biomarker strategies and functional outcome assessments\nInnovate targeted delivery approaches to improve efficacy and reduce off-target effects\nLeverage real-world data to identify meaningful\, patient-relevant endpoints\nBuild partnerships that can accelerate clinical and commercial success\n\nJoin 60+ industry experts and leading organizations including Servier\, Dyne Therapeutics\, Sanofi\, Biogen\, and Avidity Biosciences for three days of collaboration focused on overcoming the biggest challenges in muscular disorder drug development. \nWhether you’re advancing therapies for DMD\, FSHD\, DM\, LGMD\, Pompe disease\, or other rare muscle disorders\, this is the must-attend meeting to benchmark strategies\, forge new partnerships\, and help bring transformative treatments to patients faster. \nExplore the Full Agenda | Register Your Place
URL:https://www.pharmajournalist.com/event/muscular-disorders-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20261007T105805Z
CREATED:20261002T121356Z
LAST-MODIFIED:20261007T105805Z
UID:44484-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:2nd Non-Opioid Pain Therapeutics Summit
DESCRIPTION:One year on from Vertex Pharmaceuticals’ milestone JOURNAVX® approval\, making history as the first new class of pain medicine in decades\, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment\, projected to hit $124bn by 2034. \nBringing together 150+ senior leaders across pain biology\, drug discovery\, translational science\, clinical development\, medical affairs\, business development\, venture capital\, and patient advocacy\, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals\, Eli Lilly\, AbbVie\, Grünenthal\, Xenon Pharmaceuticals\, Levicept\, Tonix Pharma\, Maxona Pharmaceuticals\, 4E Therapeutics\, NIH\, Harvard Medical School\, and leading investment firms to explore emerging mechanisms\, new clinical data\, trial design innovations\, placebo mitigation strategies\, translational models\, patient-centered development approaches\, and the investment trends shaping the future of pain therapeutics. \nTo know more visit: https://ter.li/9cl7g1gn
URL:https://www.pharmajournalist.com/event/2nd-non-opioid-pain-therapeutics-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270127
DTEND;VALUE=DATE:20270130
DTSTAMP:20261028T115938Z
CREATED:20261028T115938Z
LAST-MODIFIED:20261028T115938Z
UID:44631-1801008000-1801267199@www.pharmajournalist.com
SUMMARY:8th RNAi-Based Therapeutics Summit
DESCRIPTION:The 8th RNAi-Based Therapeutics Summit returns to Boston from January 27-29\, 2027\, bringing together more than 90 industry experts working across oligonucleotide synthesis\, chemistry\, biology\, molecular design\, targeted delivery\, translational development\, and commercialization. The meeting will provide a focused forum for advancing safer\, more potent RNAi therapeutics and expanding their reach beyond traditional liver-directed applications. \nAs investment\, partnerships\, and clinical progress continue to build confidence in RNAi\, extrahepatic delivery remains one of the field’s most significant challenges. The summit will explore how next-generation delivery technologies and oligonucleotide chemistries can improve targeting selectivity\, potency\, durability\, pharmacokinetics\, pharmacodynamics\, and therapeutic index across neurology\, metabolic disease\, obesity\, cardiovascular disease\, kidney disease\, retinal disorders\, oncology\, and other high-value indications. \nAttendees will hear the latest developments in antibody-oligonucleotide conjugates\, aptamer-siRNA conjugates\, nanoparticles\, tetravalent siRNAs\, bispecific RNAi approaches\, cell-specific delivery\, and multi-target silencing strategies. Scientific presentations and panel discussions will examine how developers can cross the blood-brain barrier\, target skeletal muscle and adipose tissue\, deliver genetic medicines to the kidney\, improve retinal gene silencing\, and address complex tumor biology. \nTwo interactive pre-conference workshops will focus on identifying and validating receptors for selective extrahepatic delivery and modifying oligonucleotide chemistry to improve stability\, circulation time\, tissue exposure\, and PK/PD performance. The wider program will also address safety\, clinical translation\, commercialization\, investment\, and strategic partnerships\, helping developers progress promising candidates while reducing technical and commercial risk. \nFeaturing experts from organizations including Sanegene Bio\, Thalia Therapeutics\, Eli Lilly and Company\, Novo\, Bayer\, Bonito Biosciences\, Valaya Bio\, Judo Bio\, UMass Chan Medical School\, and Trinetra Therapeutics\, the summit offers an intimate environment for scientific exchange and meaningful collaboration. Attendees will leave with practical insights and valuable connections to support the development of the next generation of RNAi medicines. \nTo know more visit: https://ter.li/ger5rzdy
URL:https://www.pharmajournalist.com/event/8th-rnai-based-therapeutics-summit/
LOCATION:Homewood Suites by Hilton Boston Seaport District\, 670 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR